Printer Friendly
The Free Library
14,528,975 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Novartis Pharma Obtains Additional Approval for Osteoclastic Inhibitor Zometa.


Tokyo, Japan, Apr 21, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Novartis Pharma announced on April 20 that it had obtained additional approval for Zometa Injection 4mg, its proprietary osteoclastic inhibitor, from the Ministry of Health, Labor and Welfare.

The agent is currently available for the treatment of bone metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases  
1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to
 in multiple myeloma multiple myeloma

A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility
 (MM) and solid tumor tumor: see neoplasm. . Zometa, a bisphosphonate agent, is currently available in over 90 countries worldwide.

This is the first agent for bone lesion in MM and solid tumor that has been approved in Japan. Novartis Phama plans to co-promote the agent with Nippon Kayaku.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Apr 21, 2006
Words:103
Previous Article:Dainippon Sumitomo Pharma Receives Approval for Antifungal Agent AmBisome.
Next Article:Chugai Pharmaceutical Files New Drug Application for Anti-tumor Agent Bevacizumab.



Related Articles
ADVISORY/FDA Approves Novartis Agent ZOMETA For Treatment of Hypercalcemia of Malignancy.
Multimedia Available/FDA Approves Novartis Drug ZOMETA -- Zoledronic Acid for Injection -- for the Treatment of Cancer-Related Bone Complications.
ARIAD Research Highlights Beneficial Profile of Its Promising Product to Treat Cancer That Has Spread to Bone.
Research and Markets: Bisphosphonates Update - The Treatment and Prevention of Bone Metastases in Breast and Prostate Cancer.
Alfresa Pharma to Become Distributor of Anafranil Antidepressant.
Novartis Creates Japanese Holding Company.
Novartis Pharma Files Applicaion Seeking Additional Indication for Glivec in Japan.
Novartis Pharma to Market Femara, Ethical Agent for Postmenopausal Breast Cancer, in Japan.
Examine How Bisphosphonates is Used in the Treatment of Bone Metastases and Bone Loss.
Novartis and Mochida Pharmaceutical to Co-promote Diovan in Japan.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles